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Abbreviations
and Acronyms
CI = conﬁdence interval
CV = coefﬁcient of variation
Ea = arterial elastance
Ea/Eessb = ventricular-
arterial coupling, single beat
EDV = end-diastolic volume
Ees = end-systolic elastance
Eessb = end-systolic
elastance, single beat
EF = ejection fraction
ESP = end-systolic pressure
volume
ESPVR = end-systolic
pressure-volume relationship
ESV = end-systolic volume
HF = heart failure
HR = hazard ratio
IQR = interquartile range
LV = left ventricular
LVOT = left ventricular
outﬂow tract
NT-proBNP = N-terminal
pro–B-type natriuretic peptide
NYHA = New York Heart
Association
SV = stroke volume
V0 = ventricular volume
at an end-systolic pressure
of 0 mm Hg
V100 = ventricular volume
at an end-systolic pressure
of 100 mm Hg
VA = ventricular-arterial
VAD = ventricular assist
device
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1166of these components is invasive
pressure-volume analysis, but
validated noninvasive approaches
have also been developed (Fig. 1)
(2,3). Left ventricular (LV) end-
diastolic volume (EDV) is an
index of LV size and quantiﬁes
the degree of cardiac remodeling.
The end-systolic pressure volume
relationship (ESPVR) provides
a load-independent measure of
contractile function. The ESPVR
is typically assumed to be linear
and is therefore deﬁned by
a slope and an intercept (4).
Although many studies focus on
the slope alone, both the slope
(end-systolic elastance [Ees]) and
the intercept (V0) are required to
describe the contractile state of
the left ventricle. Ees quantiﬁes
ventricular elastance (stiffness)
at end-systole, and V0 is a mea-
sure of ventricular volume at a
theoretical end systolic pressure
of 0 mm Hg. Because V0 is an
extrapolated value obtained at
a nonphysiological pressure, the
ventricular end-systolic volume
(ESV) at a systolic pressure of
100 mm Hg (V100) is also often
described. Effective arterial ela-
stance (Ea), the negative slope
joining the end-systolic pressure-
volume point to the point on
the volume axis at end-diastole,
provides an integrative measure
of arterial load. The net inter-
action of the ventricular and ar-Volume (ml)
Pr
V0 ESV EDV   
Figure 1 Pressure-Volume Relationship
The parameters of left ventricular size, function, and ventricular arterial coupling
derived in this study. End-systolic elastance (Ees) represents the slope of the
end-systolic pressure volume relationship (ESPVR) where ESP denotes end-systolic
pressure, and Eessb represents the noninvasively derived single-beat estimation
of this parameter. EDV is the end-diastolic volume, and ESV is the end-systolic
volume. V0 is the intercept of the ESPVR at an end-systolic pressure of 0 mm Hg,
and V100 is the point on the end-systolic pressure volume line at an end-systolic
pressure of 100 mm Hg. Effective arterial elastance (Ea) represents the negative
slope joining the end-systolic pressure volume point to the point on the volume
axis at end-diastole, where SV represents stroke volume.terial systems is indexed by the ratio Ea/Ees, which strongly
inﬂuences cardiovascular performance and efﬁciency (4–6).
Despite noninvasive methods to assess these parameters,
their relative importance in determining HF prognosis is
unknown.
We sought to compare the impact of the component parts
of EF (cardiac size, contractile function, and ventricular-
arterial [VA] interaction) on prognosis in chronic HF. A
secondary objective of this study was to assess the feasibility of
ascertaining noninvasively derived, single-beat measures of
ventricular and arterial elastance in a large cohort of patients
with HF and reduced EF. We performed rigorous quanti-
tative 2-dimensional echocardiography analyses in a sub-
cohort of 466 patients from the Penn Heart Failure
Study, an ambulatory population composed of participants
with primarily systolic dysfunction. We determined the
relationships between EF, ventricular size (EDV), contractilefunction (Eessb and V0), and VA coupling (Ea/Eessb) and the
following clinical outcomes: 1) the combined endpoint of
death, cardiac transplantation, and ventricular assist device
(VAD) placement; and 2) cardiac hospitalization.Methods
Study population. The Penn Heart Failure Study is a
prospective cohort study of outpatients with primarily
chronic systolic HF recruited from referral centers at the
University of Pennsylvania (Philadelphia, Pennsylvania),
University of Wisconsin (Madison, Wisconsin), and Case
Western (Cleveland, Ohio) (7–9). This substudy consisted
of subjects recruited from the University of Pennsylvania
representative of the clinical site. The primary inclusion
criterion was a clinical diagnosis of HF. Participants were
excluded if they had a noncardiac condition resulting in an
expected mortality of <6 months, as judged by the treating
physician, or if they were unable or unwilling to provide
informed consent.
At time of study entry, detailed clinical data were obtained
using a standardized questionnaire administered to the
patient and treating physician, with veriﬁcation by medical
records. Two-dimensional transthoracic echocardiography
was performed in all patients at an Intersocietal Commission
for the Accreditation of Echocardiography Laboratories
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1167(ICAEL)-accredited laboratory, typically within 60 days of
study entry.
Follow-up events including all-cause mortality, cardiac
transplantation, VAD placement, and any cardiac hospital-
izations were prospectively ascertained every 6 months by
direct patient contact and veriﬁed by death certiﬁcates,
medical records, and contact with patients’ family members
by dedicated research personnel.
All participants provided written, informed consent, and
the Penn Heart Failure Study protocol was approved by the
institutional review board.
Quantitative echocardiography. Digital echocardiograms
were analyzed on TomTec computer workstations (TomTec
Imaging Systems, Unterschleissheim, Germany). Apical
4-chamber LVEDV andESVwere obtained using Simpson’s
method of disks as recommended by the American Society
of Echocardiography (3). LV volumes and mass were indexed
to body surface area, which was determined using the Dubois
formula: (0.20247  height (m)0.725  weight (kg)0.425).
ESP was estimated as 0.90 systolic pressure, obtained by
manual blood pressure cuff measurement (2). Stroke volume
(SV) was measured from the LV outﬂow tract (LVOT)
diameter and the pulse wave Doppler signal (2). EF was
calculated from 2-dimensionally derived LVOT area and
the SV (10). Effective Ea was deﬁned as the ratio of ESP/SV
(10). Ees was determined using a modiﬁed single-beat
algorithm described by Chen et al. (2) using arm cuff pres-
sures, echocardiography-derived Doppler SVs, and several
timing intervals (isovolumic contraction time, pre-ejection
period, ejection time, total systolic period) and is denoted
as Eessb (2). Ventricular-vascular coupling was estimated
by the Ea/Eessb ratio. Additional indices of the ESPVR and
LV size, V0 and V100, were also estimated from Eessb, ESV,
and ESP.
Approximately 5% of the patients had LV apical tracings
of limited image quality that precluded adequate quantita-
tion. Doppler tracings, timing intervals, and LVOT diam-
eter could not be obtained in w5% to 8% of participants
secondary to limitations in image quality. After exclusion
of these individuals, we had a complete dataset of 466
participants.
For EDVs, the intraobserver coefﬁcients of variation
(CVs) for this measurement in our core lab are 4.5% to
6.3%. The intra- and interobserver CVs for Eessb are 8.2%
and 9.8% and for Ea are 7.9% and 8.6%, respectively. The
intra- and interobserver CVs for SV based on the LVOT
method are 7.9% and 8.6%, and the intraobserver CV for
EF is 10%.
Laboratory analyses. N-terminal pro–B-type natriuretic
peptide (NT-proBNP) was measured from banked plasma
obtained at the time of study entry by a standard elec-
trochemiluminesence immunoassay (Elecsys proBNP,
Roche Diagnostics, Indianapolis, Indiana), as previously
described (11). The assay range was 20 to 5,000 pg/ml.
The intra-assay and interassay CVs were 2.9% and 6.1%,
respectively.Statistical methods. Baseline characteristics were summa-
rized for all participants using standard descriptive statistics.
Echocardiographic parameters were evaluated according
to the New York Heart Association (NYHA) functional
class using the Kruskal-Wallis rank sum test, and the rela-
tionships between echocardiographic parameters and NT-
proBNP were assessed using Spearman rank correlations.
Cox regression models were used to determine the associa-
tion between EF, EDV, Ea, Eessb, Ea/Eessb, and V0 and
V100, and risk of the combined outcome of all-cause death,
cardiac transplantation, or VAD placement. To facilitate the
comparison of associations across echocardiographic indices,
each index was categorized according to tertiles of its
distribution. Adjustment variables were selected based on
clinical rationale and included age, sex, race, height, weight,
heart rate, HF etiology, and medication use (angiotensin-
converting enzyme inhibitors, angiotensin receptor blockers,
aldosterone antagonists, and beta-blockers). Age exhibited
nonproportional hazards and was adjusted for using a time-
varying covariate, which was obtained by interacting age
with the natural log of time. A priori, adjustment for cardiac
resynchronization or deﬁbrillator therapy was not made due
to confounding by indication between presence/absence of
device therapy and degree of ventricular dysfunction.
Recurrent event models were used to determine the associ-
ation between echocardiographic indices and risk of incident
cardiac hospitalization. A joint frailty model was used to
accommodate informative censoring by all-cause death,
cardiac transplantation, or VAD placement (12). Model
complexity precluded adjustment for multiple confounders.
Finally, as the primary objective of our analyses was to
compare the strength of association across echocardiographic
metrics and not the independent associations or incremental
value of these measures, we did not place multiple echo-
cardiographic parameters in a single multivariable model,
particularly given that many of these parameters are derived
from one another, physiologically interdependent, and
highly correlated (Online Fig. 1).
All analyses were completed using R 2.15 (R Develop-
ment Core Team, Vienna, Austria), including the frailty
pack extension package (13), and Stata version 12 (Stata-
Corp., College Station, Texas).Results
Study population. Baseline characteristics of the 466
participants are detailed in Table 1. Across the cohort, the
median age was 56 years and the majority of the participants
were male (63%) and white (73%). The median EF was
27% (interquartile range [IQR]: 17% to 39%), EDV was
115 ml/m2 (IQR: 87 to 150 ml/m2), ESV was 84 ml/m2
(IQR: 58 to 117 ml/m2), and V0 and V100 were similarly
increased at 43 ml (IQR: 2.6 to 113 ml) and 167 ml (IQR:
109 to 238 ml), respectively. Across the cohort, the median
Ea was substantially elevated at 1.66 mm Hg/ml (IQR: 1.33
to 2.17 mm Hg/ml), and Eessb was markedly reduced at
Table 1 Baseline Characteristics (N = 466)
Demographic characteristics
Age, yrs 56 (46, 65)
Male 292 (63)
Race
White 340 (73)
African American 105 (23)
Other 21 (5)
Medical history and risk factors
History of hypertension 237 (51)
History of diabetes 128 (27)
Tobacco use
Never 189 (41)
Former 241 (52)
Current 36 (8)
Heart failure characteristics
NYHA functional class
I 66 (14)
II 185 (40)
III 164 (35)
IV 51 (11)
Ischemic etiology 121 (26)
Cardiac resynchronization therapy 113 (24)
Deﬁbrillator 194 (42)
Medication use
ACE inhibitor or ARB 398 (85)
Aldosterone antagonist 176 (38)
Beta-blocker 401 (86)
Diuretics 376 (81)
Clinical measurements
Height, m 1.73 (1.65, 1.80)
Weight, kg 82 (69, 97)
BSA, m2 2.0 (1.8, 2.2)
Systolic blood pressure, mm Hg 109 (96, 124)
Diastolic blood pressure, mm Hg 68 (60, 76)
End-systolic blood pressure, mm Hg 98 (86, 112)
Heart rate, beats/min 74 (64, 84)
eGFR, ml/min/1.73 m2 69 (52, 85)
Echocardiographic measurements
Effective arterial elastance (Ea), mm Hg/ml 1.66 (1.33, 2.17)
End-systolic elastance (Eessb), mm Hg/ml 0.89 (0.69, 1.18)
Ea/Eessb 1.92 (1.43, 2.54)
Ejection fraction, % 27 (17, 39)
LV mass/BSA, g/m2 130 (105, 156)
LV volume at end-diastole, ml 229 (168, 299)
LV volume at end-diastole/BSA, ml/m2 115 (87, 150)
LV volume at end-systole, ml 168 (111, 229)
LV volume at end-systole/BSA, ml/m2 84 (58, 117)
Stroke volume, ml 59 (45, 76)
Isovolumic contraction time, ms 110 (90, 137)
Ejection time, ms 239 (207, 270)
V0, ml 43 (2.6, 113)
V100, ml 167 (109, 238)
Values are median (25th, 75th percentiles) or n (%).
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; BSA ¼ body surface
area; eGFR ¼ estimated glomerular ﬁltration rate; LV ¼ left ventricular; V0 ¼ ventricular volume at
end-systolic pressure of 0 mm Hg; V100¼ ventricular volume at end-systolic pressure of 100 mm Hg.
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11680.89 mm Hg/ml (IQR: 0.69 to 1.18 mm Hg/ml) (14). The
VA coupling ratio (Ea/Eessb) was near 2.0 (median: 1.92;
IQR: 1.43 to 2.54), more than twice the value observed in
similarly aged, nonfailing subjects (range 0.62 to 0.69) (14).
Associations between echocardiographic parameters and
HF severity. We then determined the relationships between
these echocardiography-derived measures of size, contractile
function, and VA coupling and 2 commonly accepted
measures of HF severity: NYHA functional class and serum
NT-proBNP levels. As expected, EF and EDVwere strongly
associated with NYHA functional class (Table 2). Ea and
Ea/Eessb were also strongly associated NYHA functional
Class, but Eessb was not. V0 and V100, measures indicative of
the ESPVR and LV size, were also strongly associated with
NYHA functional class. NT-proBNP was signiﬁcantly
correlated with EF (r¼0.48; p< 0.001), EDV (r¼ 0.35;
p < 0.001), Ea (r ¼ 0.28; p < 0.001), Ea/Eessb (r ¼ 0.31;
p < 0.001), V0 (r ¼ 0.31; p < 0.001), and V100 (r ¼ 0.40;
p < 0.001). NT-proBNP was not correlated with Eessb
(r ¼ 0.07; p ¼ 0.21).
These ﬁndings suggest that there are signiﬁcant rela-
tionships between clinical and laboratory measures reﬂective
of HF severity and echocardiographic parameters reﬂective
of cardiac size (EDV), function and remodeling (V0) arterial
load (Ea), and coupling (Ea/Eessb). Interestingly, end-
systolic elastance as assessed by Eessb alone was not related
to these measures of HF severity.
Associations between echocardiographic parameters and
death, cardiac transplantation, and VAD. Over a median
follow-up of 3.4 years, there were 141 events, including
76 deaths, 52 transplantations, and 14 VAD placements. EF
was strongly associated with these outcomes, with a greater
than 3-fold risk in unadjusted and adjusted models when
comparing the third and ﬁrst tertiles (Table 3, Fig. 2).
EDV was also signiﬁcantly associated with adverse out-
comes, with a hazard ratio (HR) of 2.7 (95% conﬁdence
interval [CI]: 1.8 to 4.0; p < 0.001, third tertile vs. ﬁrst
tertile) in unadjusted models. After adjustment for age, sex,
race, height, weight, heart rate, HF etiology, and medication
use including angiotensin-converting enzyme inhibitors,
angiotensin receptor blockers, aldosterone antagonists, and
beta-blockers, this risk was similar (HR: 2.6, 95% CI: 1.5 to
4.2, p < 0.001; third tertile vs. ﬁrst EDV tertile). For Ea, in
unadjusted models comparing the third and ﬁrst tertiles,
those patients with an Ea 2.00 mm Hg/ml had a 1.7-fold
increased risk of adverse outcomes compared with those
patients with an Ea <1.44 mm Hg/ml (95% CI: 1.2 to 2.6,
p ¼ 0.008) (Table 3, Fig. 2). After adjustment for potential
confounders, this association remained signiﬁcant (HR: 1.7,
95% CI: 1.1 to 2.6, p ¼ 0.028). In contrast, Eessb alone was
not signiﬁcantly associated with adverse outcomes in unad-
justed or adjusted models (p > 0.05 for both). Both V0 and
V100 were strongly associated with outcomes in unadjusted
(HR: 4.0, 95% CI: 2.5 to 6.4, p< 0.001 for V0 and HR: 3.5,
95% CI: 2.2 to 5.3 for V100, p < 0.001, comparing third
and ﬁrst tertiles) and fully adjusted (HR: 3.6, 95% CI: 2.1 to
Table 2 Summary Statistics for Echocardiographic Measurements by NYHA Functional Class
NYHA Functional Class
I (n ¼ 66) II (n ¼ 185) III (n ¼ 164) IV (n ¼ 51) p Value*
Systolic blood pressure, mm Hg 112 (102, 124) 110 (98, 124) 104 (94, 124) 100 (90, 109) <0.001
Diastolic blood pressure, mm Hg 70 (62, 80) 70 (60, 76) 68 (60, 76) 62 (56, 70) 0.002
End-systolic blood pressure, mm Hg 101 (92, 112) 99 (88, 112) 94 (84, 112) 90 (81, 98) <0.001
Ejection fraction, % 37 (26, 51) 29 (20, 41) 22 (15, 35) 15 (10, 26) <0.001
Ea, mm Hg/ml 1.51 (1.14, 1.86) 1.62 (1.30, 2.11) 1.79 (1.39, 2.26) 1.78 (1.41, 2.56) 0.001
Eessb, mm Hg/ml 0.89 (0.73, 1.16) 0.91 (0.72, 1.25) 0.88 (0.68, 1.15) 0.79 (0.58, 1.10) 0.21
Ea/Eessb 1.55 (1.20, 2.24) 1.80 (1.36, 2.34) 2.10 (1.59, 2.67) 2.46 (1.78, 3.41) <0.001
LV volume at end-diastole, ml 190 (156, 250) 214 (159, 272) 250 (192, 310) 319 (192, 391) <0.001
Stroke volume, ml 71 (58, 85) 62 (46, 77) 53 (42, 72) 50 (33, 63) <0.001
Isovolumic contraction time, ms 113 (92, 130) 110 (88, 130) 110 (92, 140) 115 (80, 145) 0.47
Ejection time, ms 252 (230, 284) 243 (213, 271) 230 (205, 257) 210 (182, 235) <0.001
V0, ml 1.0 (18, 54) 31 (7.0, 94) 58 (13, 136) 96 (31, 195) <0.001
V100, ml 121 (96, 161) 157 (108, 209) 185 (137, 260) 278 (154, 331) <0.001
Values are median (25th, 75th percentiles). *p values obtained from Kruskal-Wallis rank sum test.
NYHA ¼ New York Heart Association; other abbreviations as in Table 1.
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11696.1, p < 0.001 for V0 and HR: 2.9, 95% CI: 1.7 to 4.8,
p < 0.001 for V100) models. When both Eessb and V0 were
placed in a single model, V0 retained its signiﬁcance in both
unadjusted (HR: 4.2, 95% CI: 2.6 to 6.7, p < 0.001) and
adjusted (HR: 3.8, 95% CI: 2.2 to 6.4, p < 0.001) models,
whereas Eessb remained nonsigniﬁcant (p > 0.05). VA
coupling (Ea/Eessb) was also signiﬁcantly associated with
adverse clinical outcomes in unadjusted (HR: 2.6, 95% CI:
1.7 to 4.0, p < 0.001) and fully adjusted (HR: 2.1, 95%
CI: 1.3 to 3.3, p ¼ 0.002) models, with a greater than 2-fold
increased risk of adverse outcomes in patients in the highest
tertile compared with the lowest. Overall, these ﬁndings
suggest that EDV, V0, and VA interaction (Ea/Eessb)
are the physiological determinants of EF that are most
strongly associated with prognosis in humans with systolic
dysfunction.
Associations between echocardiographic parameters and
cardiac hospitalization. Over a median follow-up of
3.4 years, 272 participants (58% of 466) experienced 684
cardiac hospitalizations before death, transplantation, or
VAD placement: 115 (25%) had 1; 62 (13%) had 2; and 95Table 3
Associations Between Echocardiographic Parameters and R
Ventricular Assist Device Implantation
Echocardiographic Parameter
Model 1*
HR (95% CI)
Ejection fraction (<19% vs. 35%) 3.8 (2.4–6.0)
EDV (266 vs. <189 ml) 2.7 (1.8–4.0)
Ea (2.00 vs. <1.44 mm Hg/ml) 1.7 (1.2–2.6)
Eessb (1.07 vs. <0.76 mm Hg/ml) 0.75 (0.51–1.1)
Ea/Eessb (2.34 vs. <1.60) 2.6 (1.7–4.0)
V0 (86 vs. <11 ml) 4.0 (2.5–6.4)
V100 (206 vs. <126 ml) 3.5 (2.2–5.3)
*Model 1: unadjusted. yModel 2: adjusted for age (time varying), sex, race, height, weight, heart rate,
antagonists, beta-blockers.
CI ¼ conﬁdence interval; EDV ¼ end-diastolic volume; HR ¼ hazard ratio comparing third and ﬁrst tertile(20%) had 3. EF was strongly associated with an increased
risk of cardiac hospitalization (HR: 2.4, CI: 1.8 to 3.2,
p < 0.001 comparing those patients with an EF <19% with
those with an EF 35%) (Table 4). EDV was also signiﬁ-
cantly associated with cardiac hospitalization, with a similar
effect size (HR: 2.1, 95% CI: 1.6 to 2.9, p < 0.001).
Individually, Ea was not signiﬁcantly associated with cardiac
hospitalization, and the association of Eessb was of marginal
signiﬁcance in unadjusted models. However, V0 and V100
were signiﬁcantly associated with cardiac hospitalization
(HR: 2.3, 95% CI: 1.8 to 3.1, p< 0.001 for V0 and HR: 2.5,
95% CI: 1.9 to 3.3, p < 0.001 for V100 comparing third and
ﬁrst tertiles). V0 remained signiﬁcant when Eessb and V0
were placed in a single model (HR: 2.5, 95% CI: 1.9 to 3.3,
p < 0.001), whereas Eessb was not. Ea/Eessb was associated
with a greater than 2-fold increased risk when comparing
the third and ﬁrst tertiles (Ea/Eessb 2.34 vs. 1.60; HR: 2.1,
95% CI: 1.6 to 2.9, p < 0.001). Overall, our ﬁndings were
consistent across both sets of clinical outcomes: death,
cardiac transplantation, and VAD placement and cardiac
hospitalization.isk of All-Cause Mortality, Cardiac Transplantation, or
Model 2y
p Value HR (95% CI) p Value
<0.001 3.0 (1.8–5.0) <0.001
<0.001 2.6 (1.5–4.2) <0.001
0.008 1.7 (1.1–2.6) 0.028
0.16 0.97 (0.63–1.5) 0.88
<0.001 2.1 (1.3–3.3) 0.002
<0.001 3.6 (2.1–6.1) <0.001
<0.001 2.9 (1.7–4.8) <0.001
heart failure etiology, angiotensin-converting enzyme/angiotensin receptor blockers, aldosterone
s with cut points for each measurement provided in parentheses; other abbreviations as in Table 2.
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Figure 2 Event-Free Survival According to Echocardiographic Parameters
Kaplan-Meier survival estimates for all-cause death, cardiac transplantation, or ventricular assist device placement according to tertiles of echocardiography-derived
parameters: ejection fraction (EF) (A), effective arterial elastance (Ea) (B), end-systolic elastance (end-systolic elastance, single beat [Eessb]) (C), ventricular arterial
coupling (Ea/Eessb) (D), V0 (E), and end-diastolic volume (EDV) (F). p < 0.001 for EF; p ¼ 0.027 for Ea; p ¼ 0.30 for Eessb; and p < 0.001 for Ea/Eessb, V0, and EDV by log-rank
test. Continued on the next page.
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1170Discussion
EF is an easily obtained and widely used parameter that
has unequivocal prognostic importance in human HF. Our
primary objective in this study was to compare the strength
of the associations of the physiological determinants of
EF–LV size (EDV), contractile function (Eessb and V0),
and VA coupling (Ea/Eessb) with adverse outcome. In
a large cohort of 466 patients with HF and reduced EF, we
found that EDV, V0, and VA coupling (Ea/Eessb) were
strongly associated with NYHA functional class, increase innatriuretic peptides, and adverse clinical outcomes.
Surprisingly, Eessb, a noninvasive measure of the slope of the
ESPVR (Fig. 1), showed no signiﬁcant associations with
adverse outcomes. Our results suggest that in the setting of
chronic HF, the extent of ventricular remodeling and VA
coupling are important indicators of prognosis, whereas Ees
is not.
These ﬁndings reinforce the well-known hemodynamic
importance of aggressive afterload reduction in HF with
reduced EF and demonstrate that the pathophysiological
signiﬁcance of chamber elastance alone is less relevant than
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1171the matching of ventricular and arterial elastance. For
maximal cardiac work, power, and efﬁciency, the coupling
ratio of Ea/Ees typically resides between 0.5 and 1.2 (15,16).
In failing hearts, this ratio increases as cardiac function
declines and arterial load increases to maintain systolic
pressure (17–20). At excessively high ratios, ventricular-
vascular matching is signiﬁcantly compromised, leading to
inefﬁcient and ineffective contraction (21).
As expected, we found that Ees, as assessed by Eessb, was
low in chronic HF patients (22), but the absence of any
association between Eessb and adverse outcomes was initially
counterintuitive. There are a number of potential reasons for
this ﬁnding. First, there is a possibility of measurement
error, although this is less likely given that our calculated
methods were derived using an algorithm that was veriﬁed
using comparisons with invasive analyses (2). Furthermore,
our reproducibility data suggest acceptable, low CVs.
Second, as revealed in patients with HF with preserved EF,
normal Eessb can exist despite abnormal systolic and dia-
stolic function (10,14,22). Third, and most importantly, Ees
alone is not a comprehensive measure of contractile function.
Fully describing the contractile state of the ventricle requires
speciﬁcation of both the slope (Ees) and the intercept (V0) ofTable 4
Associations Between Echocardiographic Parameters
and Risk of Cardiac Hospitalization
Echocardiographic Parameter HR (95% CI) p Value
Ejection fraction (<19% vs. 35%) 2.4 (1.8–3.2) <0.001
EDV (266 vs. <189 ml) 2.1 (1.6–2.8) <0.001
Ea (2.00 vs. <1.44 mm Hg/ml) 1.3 (0.9–1.7) 0.10
Eessb (1.07 vs. <0.76 mm Hg/ml) 0.72 (0.5–1.0) 0.039
Ea/Eessb (2.34 vs. <1.60) 2.1 (1.6–2.9) <0.001
V0 (86 vs. <11 ml) 2.3 (1.8–3.1) <0.001
V100 (206 vs. <126 ml) 2.5 (1.9–3.3) <0.001
Abbreviations as in Table 3.the ESPVR, and in fact we detected a strong association
between V0 and prognosis. In this sense, our data indicate
a strong association between the contractile function of
the heart and adverse outcome. However, we also note the
V0 and EDV are highly correlated (R ¼ 0.73) (Online
Fig. 1), suggesting that it may be impossible to completely
separate and independently measure chamber remodeling
and contractile dysfunction in the intact human heart.
Finally, it may also be that in our population, one of chronic
HF on optimal medical therapy, VA coupling and the
interaction between the ventricular and vascular systems is
more important than the LV Eessb alone. Overall, the
absence of the relationship between Eessb and adverse
outcomes suggests that assessing chamber function via Ees
alone is insufﬁcient to gauge prognosis in human HF.
Previous studies have used precise, invasive measurements
or multigated acquisition–derived estimations to demon-
strate Ea and Eessb mismatch in small samples sizes of
systolic HF, but were insufﬁciently powered to test rela-
tionships with clinical outcome (17,23). Our study corrob-
orates these ﬁndings of Ea and Eessb mismatch in a larger
population and also reveals that Ea and Ea/Eessb are strong
predictors of adverse clinical outcomes. Similarly, the
importance of arterial load in HF demonstrated here indi-
cates the need for better characterization of arterial proper-
ties and their impact on outcomes in this population.
Noninvasive characterization of aortic pressure-ﬂow rela-
tionships are feasible and should yield further insight into
the role of arterial load in HF in future research.
Study limitations. Echocardiography is inherently limited
by image quality and observer variability. In our study,
however, all echocardiograms were comprehensively
analyzed in our core lab by a sonographer with 30 years of
experience, <10% of echocardiograms were unanalyzable,
and CVs were low. The methods to estimate parameters
such as Eessb were previously validated by comparing Eessb
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1172with invasively measured Ees from pressure-volume rela-
tionships in humans, but still represent noninvasive esti-
mations of Ees. Although our work provides important
insight into myocardial mechanics during systole, we did not
assess diastolic ventricular stiffness. It is also possible that
our estimations could be improved by tonometry-derived
and 3-dimensional echocardiography–derived measures
(24), which are the subject of future work. We also did not
have measures of myocardial contractility such as midwall
fractional shortening, which may have provided additional
insight into the lack of association between Eessb and
outcomes.
There are important potential implications of our ﬁnd-
ings. The coupling ratio Ea/Eessb is an easily derived
physiological measure that may be used to assess prognosis
and response to therapy. For example, Ea/Eessb could be
used as a measure to gain insight into the changes that occur
with ventricular and vascular function with novel pharma-
cological or device therapies or with cardiotoxic agents. We
may also gain insight into whether longitudinal changes over
time affect prognosis. Large-scale assessment of VA
coupling in population-based studies and clinical trials has
the potential to provide us with an improved conceptual
framework for understanding HF.
Conclusions
Noninvasively derived measures of ventricular vascular
mechanics can be easily derived from a routine echocardio-
gram in patients with marked systolic dysfunction. These
measures are altered in HF with reduced EF, and the extent
of LV remodeling and ventricular-vascular uncoupling is
strongly associated with adverse clinical outcomes. With
further study, these measures can be used to gain better
insight into the effects of interventions on cardiac function,
suggesting that EDV, V0, and Ea/Eessb are potential ther-
apeutic targets.
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